XSHE
002742
Market cap417mUSD
Oct 09, Last price
4.19CNY
1D
2.44%
1Q
13.55%
Jan 2017
-62.35%
IPO
-38.94%
Name
Chongqing Sansheng Industrial Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Chongqing Sansheng Industrial Co.,Ltd. is a Chinese enterprise specializing in the research, development, production, and sale of a diverse range of products, spanning both building materials and chemicals, as well as pharmaceuticals. Within its building materials and chemical segment, the company supplies essential construction inputs such as commercial concrete, water-reducing agents, and expansion agents. These products find extensive application across various large-scale infrastructure projects, including industrial and residential buildings, highways, railways, bridges, tunnels, airports, and water conservancy facilities. Additionally, Sansheng Industrial manufactures sulfuric acid, a key chemical component vital for the production of chemical fertilizers, general industrial chemicals, light industry products, textiles, steel, and water reducer formulations, among other non-fertilizer acidic compounds. The company also maintains a significant presence in the pharmaceutical sector. Its offerings here encompass pharmaceutical intermediates, exemplified by procaine hydrochloride, cefoxitin intermediate, chloramphenicol intermediate, aztreonam intermediate, and orlistat intermediate, which are crucial precursors for antibiotic drugs, anti-hepatitis C treatments, diabetes medications, specific penicillin variants, and cosmetic formulations. Furthermore, Sansheng produces active pharmaceutical ingredients (APIs) such as acetaminophen, cloperidine hydrochloride, levofloxacin mesylate, benoate, and diphenhydramine hydrochloride. Its range of finished pharmaceutical preparations includes compound paracetamol diphenhydramine, clarithromycin sustained-release, diclofenac sodium enteric-coated, and famotidine tablets, designed for diverse therapeutic applications like antipyretic and analgesic effects, antiviral, antibacterial, cough relief, allergy management, and local anesthesia. Beyond these, the company provides a selection of clinically significant drugs, including famotidine, diclofenac sodium, nifedipine, acetaminophen, furosemide, and norfloxacin. Established in 2002, the company was initially known as Chongqing Sansheng Special Building Materials Co., Ltd. before officially adopting its current name, Chongqing Sansheng Industrial Co.,Ltd., in October 2016. Its operations are headquartered in Chongqing, China.
Key people
Weiwei Duan
Vice Chairman of the Board · since 2025
Xuemei Liu
Chief Financial Officer · since 2025
Zhongqiang Huang
General Manager · since 2025
Yongting Dong
Deputy General Manager · since 2025
Xuying Gao
Deputy General Manager · since 2025
Xiaoyou Zhang
Secretary of the Board · since 2022
Jing Liang
Director
Shengyi Ma
Director · since 2025
Yingjian Song
Chairman of the Board · since 2025
Dong Wei
Director · since 2025
Huan Yan
Director · since 2025
Jian Zhang
Staff Elected Director · since 2025
Xiaodong Cong
Independent Director · since 2025
Chao Huang
Independent Director · since 2025
Jinruo Zhang
Independent Director · since 2025
Headquarters & legal address
重庆市北碚区三圣镇街道
北碚区, CQ 400000
CN
北碚区, CQ 400000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||